TRI and ICON to Provide Clinical Support Services to the National Institute of Allergy and Infectious Diseases

Jun 29, 2010, 06:10 ET from Technical Resources International, Inc.

BETHESDA, Md., June 29 /PRNewswire/ -- Technical Resources International, Inc. (TRI) is pleased to announce that TRI and its subcontractor ICON Clinical Research, Inc. (ICON) have been awarded the Clinical Research Operations and Management Support (CROMS) contract by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.  An initial award of $19 million was received; the contract has a potential total value of up to $171 million over 7 years.

(Logo: http://photos.prnewswire.com/prnh/20100629/PH27969LOGO-b )

(Logo: http://www.newscom.com/cgi-bin/prnh/20100629/PH27969LOGO-b )

Under the CROMS contract, TRI and ICON will provide NIAID's Division of Microbiology and Infectious Diseases (DMID) with support for protocol development, clinical site monitoring, training, pharmacovigilance, the CROMS information data system, and quality management.

DMID supports extramural research to control and prevent diseases caused by virtually all human infectious agents except HIV.  A fundamental component of DMID's endeavors is the assessment of new and enhanced vaccine and therapeutic candidates in clinical trials and clinical studies. Through a widespread network of grant and contract research programs, DMID supports an extensive range of clinical research, including Phase 1, Phase 2, Phase 3, and Phase 4 clinical trials.  DMID supports research on bacterial, viral and parasitic vaccines, therapeutics, and other biologics and drugs as preventive and therapeutic measures against infectious diseases.

Commenting on the contract award, Nora Lee, TRI's President and CEO expressed, "TRI is pleased to have established a successful team with ICON Clinical Research, Inc. to support the DMID-CROMS mission."  John Hubbard, Group President Clinical Research Services at ICON, added, "ICON is delighted to be working with TRI, who has over 30 years of experience working with Federal health programs.  ICON will be seeking to leverage its global infrastructure and experience to support this important U.S. government program."

DMID supports a wide variety of projects spanning the spectrum from basic research through applied research, along with the development and clinical evaluation of new drugs, vaccines, and diagnostics.

About TRI: Technical Resources International, Inc. is a full-service contract research organization.  TRI's areas of expertise include clinical trials management, regulatory affairs, medical writing, safety & pharmacovigilance, quality assurance, information technology, and communications.  For over 30 years, TRI has provided support to government agencies, the private sector, and non-profit organizations.  Further information is available at www.tech-res.com.

About ICON:  ICON Clinical Research, Inc. is a wholly owned subsidiary of ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries.  The company specializes in the strategic development, management and analysis of programs that support clinical development -- from compound selection to Phase I-IV clinical studies.  ICON currently operates from 71 locations in 39 countries and has approximately 7,300 employees.  Further information is available at www.iconplc.com.

SOURCE Technical Resources International, Inc.



RELATED LINKS

http://www.tech-res.com